+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities

Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities

Advanced Drug Delivery Reviews 62(2): 272-282

N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer conjugates containing doxorubicin designed in the late 1970s/early 1980s as anticancer polymer therapeutics were the first synthetic polymer-based anticancer conjugates to enter clinical trial beginning in 1994. Early clinical results were promising, confirming activity in chemotherapy refractory patients and the safety of HPMA copolymers as a new polymer platform in this setting. Subsequent Phase I/II trials have investigated conjugates containing paclitaxel (PNU 166945), camptothecin (PNU 166148) (both failed in clinical trials underlining the importance of rational design), and most recently HPMA-copolymer platinates (AP5280 and then AP5346-ProLindac(TM)) entered Phase II clinical development. There are a growing array of second generation HPMA copolymer-based systems involving combination therapy, incorporating putative targeting ligands, having an ever more complex architecture, and both drug and protein conjugates are being proposed as novel treatments for diseases other than cancer. Despite their promise, and the success of polymeric drugs and polymer-protein conjugates, no polymer-drug conjugate (HPMA copolymer-based or otherwise) has yet entered routine clinical use. It is timely to reflect on the progress made over the last 30 years, the relative merits of HPMA copolymers as a platform compared to other polymeric carriers, and comment on their future potential as polymer-based nanomedicines into the 21st century in comparison with the many alternative strategies now emerging for creation of nanopharmaceuticals.

(PDF emailed within 0-6 h: $19.90)

Accession: 052675762

Download citation: RISBibTeXText

PMID: 20005271

DOI: 10.1016/j.addr.2009.12.005

Related references

Phytochemical based nanomedicines against cancer: current status and future prospects. Journal of Drug Targeting 26(9): 731-752, 2017

Nanomedicines for cancer therapy: current status, challenges and future prospects. Therapeutic Delivery 2019, 2019

Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics. Journal of Pharmaceutical Investigation 48(1): 43-60, 2018

Design of smart HPMA copolymer-based nanomedicines. Journal of Controlled Release 240: 9-23, 2015

Comparison of the pharmacological and biological properties of HPMA copolymer-pirarubicin conjugates: A single-chain copolymer conjugate and its biodegradable tandem-diblock copolymer conjugate. European Journal of Pharmaceutical Sciences 106: 10-19, 2017

Polymer-drug conjugates: current status and future trends. Frontiers in Bioscience 13: 2744-2756, 2007

Polymer-drug conjugates current status and future trends. Frontiers in Bioscience 13: 2744-2756, 2008

Antibody-drug conjugates: Current status and future perspectives. Pharmacology and Therapeutics 167: 48-59, 2016

Antibody-drug conjugates: current status and future directions. Drug Discovery Today 19(7): 869-881, 2015

Current status and future opportunities for controlling acromegaly. Pituitary 5(3): 185-196, 2003

Chicken genome: current status and future opportunities. Genome Research 15(12): 1692-1698, 2005

Anti-obesity drugs: a critical review of current therapies and future opportunities. Pharmacology and Therapeutics 89(1): 81-121, 2001

The scope of aquaculture Current status and future problems and opportunities. Lim, C , Sessa, D J Nutrition and utilization technology in aquaculture 1-25, 1995

Terpenoid biosynthesis in trichomes--current status and future opportunities. Plant Biotechnology Journal 11(1): 2-22, 2013

Respiratory Tissue Engineering: Current Status and Opportunities for the Future. Tissue Engineering. Part B, Reviews 21(4): 323-344, 2016